The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Stage

Series A | Alive

Total Raised

$1M

Last Raised

$500K | 32 yrs ago

About Lexicor

Provider of EEG-based neuropsychiatric assessment aids. The company focus is the NEBATM, intended for use by psychiatrists, psychologists, pediatricians, and physicians in patients aged 6-17 years who have presented with attention and behavior concerns.

Lexicor Headquarter Location

753 Broad Street Suite 701

Augusta, Georgia, 30901,

United States

(706)736-5864

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lexicor

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Lexicor is included in 1 Expert Collection, including Medical Devices.

M

Medical Devices

224 items

Companies that received FDA De Novo clearances since 2010. Companies tagged as #FDADeNovos

  • Where is Lexicor's headquarters?

    Lexicor's headquarters is located at 753 Broad Street, Augusta.

  • What is Lexicor's latest funding round?

    Lexicor's latest funding round is Series A.

  • How much did Lexicor raise?

    Lexicor raised a total of $1M.

  • Who are the investors of Lexicor?

    Investors of Lexicor include Valley Ventures.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.